Selective removal of immune complexes
    1.
    发明授权
    Selective removal of immune complexes 失效
    选择性去除免疫复合物

    公开(公告)号:US5084398A

    公开(公告)日:1992-01-28

    申请号:US601029

    申请日:1990-10-23

    IPC分类号: A61M1/36 C07K14/31 C07K17/06

    摘要: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and inidivdual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.

    摘要翻译: 公开了一种可用于将血液中的免疫复合物优先地去除可溶性抗体的方法和一系列材料。 该材料包含与免疫球蛋白Fc区结合的蛋白质的类似物。 类似物通过截短或以其它方式改变结合蛋白的氨基酸序列来降低它们对Fc的亲和力而产生。 在不溶性基质的表面附近设置的这种类似物的阵列具有在复合物中形成与多个Fc的多个连接点的能力,以便强烈地结合复合物,而仅在可溶性IgG的Fc区和 inidivdual类似物。 优选的类似物是与蛋白A或蛋白G的结合部分与Fc结合的截短的蛋白质。 可以使用材料和常规的血浆置换技术从全血或血清中除去复合物。

    DNA encoding a protein which enables selective removal of immune
complexes
    2.
    发明授权
    DNA encoding a protein which enables selective removal of immune complexes 失效
    编码能够选择性去除免疫复合物的蛋白质的DNA

    公开(公告)号:US5243040A

    公开(公告)日:1993-09-07

    申请号:US787669

    申请日:1991-11-04

    摘要: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and individual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.

    摘要翻译: 公开了一种用于从血液中将免疫复合物优先地去除可溶性抗体的方法和一系列材料。 该材料包含与免疫球蛋白Fc区结合的蛋白质的类似物。 类似物通过截短或以其它方式改变结合蛋白的氨基酸序列来降低它们对Fc的亲和力而产生。 在不溶性基质的表面附近设置的这种类似物的阵列具有在复合物中形成与多个Fc的多个连接点的能力,以便强烈地结合复合物,而仅在可溶性IgG的Fc区和 个别类似物。 优选的类似物是与蛋白A或蛋白G的结合部分与Fc结合的截短的蛋白质。 可以使用材料和常规的血浆置换技术从全血或血清中除去复合物。

    Morphogen-induced dendritic growth
    4.
    发明申请
    Morphogen-induced dendritic growth 审中-公开
    形态诱导树突生长

    公开(公告)号:US20060025571A1

    公开(公告)日:2006-02-02

    申请号:US11226555

    申请日:2005-09-13

    IPC分类号: A61K38/18 C07K14/475

    摘要: Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.

    摘要翻译: 公开了用于在哺乳动物中维持神经通路的方法和组合物,包括:增加有死亡风险的神经元的存活; 诱导损伤的神经元和神经通路的细胞修复; 刺激神经元维持其分化表型; 并促进树突生长,包括保持树枝状树枝和再生树枝状结构。 在一个实施方案中,本发明提供用于刺激神经元中的CAM表达的装置。 本发明还提供用于评估神经组织状态的手段,包括用于检测和监测哺乳动物神经病变的手段。 方法,装置和组合物包括以治疗有效浓度提供给哺乳动物的形态发生剂或形态发生剂。 在另一个实施方案中,本发明提供了包括形态发生剂或形态发生剂刺激剂以及神经营养因子或神经营养因子刺激剂的方法和组合物,其浓度有效刺激枝晶生长。 形态发生剂和神经营养因子可以组合使用。

    Compensation driven network based exchange system and method
    10.
    发明申请
    Compensation driven network based exchange system and method 审中-公开
    补偿驱动网络交换系统和方法

    公开(公告)号:US20050091075A1

    公开(公告)日:2005-04-28

    申请号:US10922379

    申请日:2004-12-27

    IPC分类号: G06Q30/02 G06F17/60

    摘要: A method and system using a communication network, such as the Internet, to compensate at least one user in exchange for work undertaken by the at least one user. The communication network is used to perform work, the work being defined by a content provider in a manner which does not target specific user profiles. Compensation units are offered to the user in exchange for the performed work. The user uses a user terminal to accept the offered compensation units. The accepted compensation units are transferred from a content provider account to a user account, the content provider account corresponding to the content provider offering the compensation units and the user account corresponding to user who completed the work. The user can spend earned compensation units on goods and services offered by a redeeming content provider. The compensation units are provided in a closed system. The issuing content provider does not control how, when or where earned compensation units may be spent

    摘要翻译: 一种使用诸如因特网之类的通信网络的方法和系统来补偿至少一个用户以换取由至少一个用户进行的工作。 通信网络用于执行工作,该工作由内容提供商以不针对特定用户简档的方式定义。 向用户提供补偿单位以换取已完成的工作。 用户使用用户终端接受提供的补偿单元。 接受的补偿单元从内容提供者帐户转移到用户帐户,与提供补偿单元的内容提供商对应的内容提供商帐户和与完成工作的用户对应的用户帐户。 用户可以在赎回内容提供商提供的商品和服务上支付获得的赔偿单位。 补偿单元在封闭系统中提供。 发行内容提供商不控制如何,何时或在哪里获得赔偿单位